{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(11)"],"submitter":["Rossmann E"],"pubmed_abstract":["Patients (n = 34) with previously untreated, slowly progressive asymptomatic stage I/II multiple myeloma or with stage II/III multiple myeloma in stable response/plateau phase following conventional anti-tumor therapy were immunized repeatedly with the antigen-specific cancer immunotherapeutic agent tecemotide (L-BLP25). Additionally, patients were randomly allocated to either single or multiple low doses of cyclophosphamide to inhibit regulatory T cells (Treg). Immunization with tecemotide resulted in the induction/augmentation of a mucin 1-specific immune response in 47% of patients. The immune responses appeared to involve a Th1-like cellular immune response involving CD4 and CD8 T cells. The rate of immune responses was similar with single versus multiple dosing of cyclophosphamide and"],"journal":["Human vaccines & immunotherapeutics"],"pagination":["3394-408"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4514088"],"repository":["biostudies-literature"],"pubmed_title":["Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study."],"pmcid":["PMC4514088"],"pubmed_authors":["Lofvenberg E","von Heydebreck A","Rossmann E","Forssmann U","Mellstedt H","Osterborg A","Schroder A","Choudhury A"],"additional_accession":[]},"is_claimable":false,"name":"Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.","description":"Patients (n = 34) with previously untreated, slowly progressive asymptomatic stage I/II multiple myeloma or with stage II/III multiple myeloma in stable response/plateau phase following conventional anti-tumor therapy were immunized repeatedly with the antigen-specific cancer immunotherapeutic agent tecemotide (L-BLP25). Additionally, patients were randomly allocated to either single or multiple low doses of cyclophosphamide to inhibit regulatory T cells (Treg). Immunization with tecemotide resulted in the induction/augmentation of a mucin 1-specific immune response in 47% of patients. The immune responses appeared to involve a Th1-like cellular immune response involving CD4 and CD8 T cells. The rate of immune responses was similar with single versus multiple dosing of cyclophosphamide and","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014","modification":"2026-05-02T11:31:44.71Z","creation":"2026-04-07T18:00:02.281Z"},"accession":"S-EPMC4514088","cross_references":{"pubmed":["25483677"],"doi":["10.4161/hv.29918"]}}